Literature DB >> 31230070

Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and cause-of-death registries.

Kaj Ekström1, Jukka Lehtonen1, Hanna-Kaisa Nordenswan1, Mikko I Mäyränpää2, Anne Räisänen-Sokolowski2, Riina Kandolin1, Piia Simonen1, Päivi Pietilä-Effati3, Aleksi Alatalo4, Seppo Utriainen5, Tuomas T Rissanen6, Petri Haataja7, Jorma Kokkonen8, Tapani Vihinen9, Heikki Miettinen10, Kari Kaikkonen11, Tuomas Kerola12, Markku Kupari1.   

Abstract

AIMS: The present study was done to assess the role of sudden cardiac death (SCD) among the presenting manifestations of and fatalities from cardiac sarcoidosis (CS). METHODS AND
RESULTS: We analysed altogether 351 cases of CS presenting from year 1998 through 2015 in Finland. There were 262 patients with a clinical diagnosis and treatment of CS, 27 patients with an initial lifetime diagnosis of giant cell myocarditis that was later converted to CS, and 62 cases detected at autopsy and identified by screening >820 000 death certificates from the national cause-of-death registry. The total case series comprised 253 females and 98 males aged on average 52 years at presentation. High-grade atrioventricular block was the most common first sign of CS (n = 147, 42%) followed by heart failure (n = 58, 17%), unexpected fatal (n = 38) or aborted (n = 12) SCD (14%), and sustained ventricular tachycardia (n = 48, 14%). Severe coronary artery disease was found at autopsy concomitant with CS in four of the 38 cases presenting with fatal SCD. Of all deaths recorded till the end of 2015, 64% (n = 54/84) were unexpected SCDs from CS that had either been silent during life or defied all attempts at diagnosis. The Kaplan-Meier estimate (95% CI) of survival from symptom onset was 85% (80-90%) at 5 years and 76% (68-84%) at 10 years.
CONCLUSION: Together fatal and aborted SCD constitute 14% of the presenting manifestations of CS. Nearly two-thirds of all fatalities from CS are caused by undiagnosed granulomas in the heart. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiac sarcoidosis; Sudden cardiac death

Year:  2019        PMID: 31230070     DOI: 10.1093/eurheartj/ehz428

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  16 in total

1.  Controversies in the Treatment of Cardiac Sarcoidosis.

Authors:  Ogugua Ndili Obi; Elyse E Lower; Robert P Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2022-06-29       Impact factor: 1.803

Review 2.  Arrhythmias Associated with Inflammatory Cardiomyopathies.

Authors:  Roshan Karki; Chaitra Janga; Abhishek J Deshmukh
Journal:  Curr Treat Options Cardiovasc Med       Date:  2020-11-19

3.  Idiopathic giant cell myocarditis or cardiac sarcoidosis? A retrospective audit of a nationwide case series.

Authors:  Kaj Ekström; Anne Räisänen-Sokolowski; Jukka Lehtonen; Hanna-Kaisa Nordenswan; Mikko I Mäyränpää; Markku Kupari
Journal:  ESC Heart Fail       Date:  2020-04-28

4.  Whole-Exome Sequencing Identifies a Novel TRPM4 Mutation in a Chinese Family with Atrioventricular Block.

Authors:  Yi Dong; Ran Du; Liang-Liang Fan; Jie-Yuan Jin; Hao Huang; Ya-Qin Chen; Dan-Dong Bi; Rong Xiang
Journal:  Biomed Res Int       Date:  2021-04-17       Impact factor: 3.411

5.  Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25-Year Nationwide Cohorts.

Authors:  Hanna-Kaisa Nordenswan; Jukka Lehtonen; Kaj Ekström; Anne Räisänen-Sokolowski; Mikko I Mäyränpää; Tapani Vihinen; Heikki Miettinen; Kari Kaikkonen; Petri Haataja; Tuomas Kerola; Tuomas T Rissanen; Jorma Kokkonen; Aleksi Alatalo; Päivi Pietilä-Effati; Seppo Utriainen; Markku Kupari
Journal:  J Am Heart Assoc       Date:  2021-03-04       Impact factor: 5.501

Review 6.  Challenges in Cardiac and Pulmonary Sarcoidosis: JACC State-of-the-Art Review.

Authors:  Maria Giovanna Trivieri; Paolo Spagnolo; David Birnie; Peter Liu; Wonder Drake; Jason C Kovacic; Robert Baughman; Zahi A Fayad; Marc A Judson
Journal:  J Am Coll Cardiol       Date:  2020-10-20       Impact factor: 24.094

Review 7.  Sarcoidosis-Related Cardiomyopathy: Current Knowledge, Challenges, and Future Perspectives State-of-the-Art Review.

Authors:  Nisha A Gilotra; Jan M Griffin; Noelle Pavlovic; Brian A Houston; Jessica Chasler; Colleen Goetz; Jonathan Chrispin; Michelle Sharp; Edward K Kasper; Edward S Chen; Ron Blankstein; Leslie T Cooper; Emer Joyce; Farooq H Sheikh
Journal:  J Card Fail       Date:  2021-07-11       Impact factor: 5.712

Review 8.  Clinical Features and Diagnosis of Cardiac Sarcoidosis.

Authors:  Claudio Tana; Cesare Mantini; Iginio Donatiello; Luciano Mucci; Marco Tana; Fabrizio Ricci; Francesco Cipollone; Maria Adele Giamberardino
Journal:  J Clin Med       Date:  2021-05-01       Impact factor: 4.241

9.  Inpatient characteristics, complications, and outcomes of patients with cardiac sarcoidosis: A study from the National Inpatient Sample.

Authors:  Siva S Taduru; Amandeep Goyal; Tarun Dalia; Ioannis Mastoris; Aniket S Rali; Prakash Acharya; Robert Weidling; Andrew Sauer; Nicholas Haglund; Zubair Shah
Journal:  Indian Heart J       Date:  2022-01-31

Review 10.  Role of CMR Mapping Techniques in Cardiac Hypertrophic Phenotype.

Authors:  Andrea Baggiano; Alberico Del Torto; Marco Guglielmo; Giuseppe Muscogiuri; Laura Fusini; Mario Babbaro; Ada Collevecchio; Rocco Mollace; Stefano Scafuri; Saima Mushtaq; Edoardo Conte; Andrea Daniele Annoni; Alberto Formenti; Maria Elisabetta Mancini; Giulia Mostardini; Daniele Andreini; Andrea Igoren Guaricci; Mauro Pepi; Marianna Fontana; Gianluca Pontone
Journal:  Diagnostics (Basel)       Date:  2020-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.